Takeda Pharmaceutical Company Limited has acquired the biologics manufacturing facility located in Brooklyn Park, Minnesota, from Baxalta US Inc. Takeda intends to use the facility primarily for the manufacture of Entyvio (vedolizumab) and other biologic products. Entyvio was approved by the US Food and Drug Administration to treat adult patients with moderate to severe ulcerative colitis and adult patients with moderate to severe Crohn‘s disease.Baxalta is the biopharmaceutical company spun off from Baxter in 2015.

Takeda says the acquisition will also provide long-term strategic benefits for Takeda through enhanced capacities for the manufacture of additional commercial products and investigational drugs under clinical development. The plant allows Takeda to establish and develop direct commercial bio-manufacturing expertise. Terms of the transaction were not disclosed.

The Brooklyn Park facility is one of several manufacturing facilities of Baxalta, which also has facilities in Austria (Orth and Vienna), Belgium (Lessines), California (Howard, Los Angeles, Thousand Oaks), Italy (Pisa and Rieti), Massachusetts (Milford), Singapore (Woodlands), and Switzerland (Neuchatel). In addition to these manufacturing facilities, Baxalta is currently building a manufacturing facility near Covington, Georgia, to support the growth of its plasma-based products. The timeline on the project spans several years with commercial production scheduled to begin in 2018, according to the company’s September 1, 2015, registration filing with the US Securities and Exchange Commission The company is also expanding its manufacturing facility in Krems, Austria, with production expected to commence at the expanded facility in 2018.

Source: Takeda Pharmaceutical